# To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

> **NCT05324293** · PHASE1 · COMPLETED · sponsor: **Hope Medicine (Nanjing) Co., Ltd** · enrollment: 16 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** HMI-115

## Key facts

- **NCT ID:** NCT05324293
- **Lead sponsor:** Hope Medicine (Nanjing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324293, "To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05324293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*